Skip to main content
. Author manuscript; available in PMC: 2018 Oct 28.
Published in final edited form as: J Control Release. 2017 Aug 24;264:160–168. doi: 10.1016/j.jconrel.2017.08.029

Figure 2.

Figure 2

Representative maximum-intensity projection (MIP) of longitudinal in vivo PET images of pancreatic cancer-bearing mice administered 89Zr-Df-ALT-836 (7.4–11.1 MBq). Prominent tumor uptake of 89Zr-Df-ALT-836 was observed in mice bearing BXPC-3 xenografts (top row), while PANC-1 tumors (middle row) exhibited negligible radioactivity accumulation. Mice pre-injected with a TF-blocking dose of ALT-836 (50 mg/kg) displayed significantly lower accrual of the tracer in BXPC-3 tumors (bottom row).